FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
March 01, 2021 07:00 AM Eastern Standard Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines potentially applicable to all therapeutic targets, including those previously considered “undruggable”, today announced the Company’s $107 million Series C financing. The financing was led by venBio Partners, with participation from new investors Cormorant Asset […]
